Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

BoRa Leea Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, KoreaView further author information

Dae Gyu Kimb Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy and College of Medicine, Interdisciplinary Biomedical Center, Gangnam Severance Hospital, Yonsei University, Seoul, KoreaView further author information

Aram Leea Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, KoreaView further author information

Young Mi Kima Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, KoreaView further author information

Lianji Cuia Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, KoreaView further author information

Sunghoon Kimb Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy and College of Medicine, Interdisciplinary Biomedical Center, Gangnam Severance Hospital, Yonsei University, Seoul, KoreaCorrespondence[email protected]
View further author information

Inhee Choia Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, KoreaCorrespondence[email protected]

https://orcid.org/0000-0001-7884-1764 View further author information

show all

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date